Joyzyme Group Limited, operating under the stock name Huakang Biomed (HKEX: 08622), filed its Monthly Return of Equity Issuer for the period ended 30 April 2026.

Authorised Capital • The authorised share capital remained unchanged at 1.00 billion ordinary shares with a par value of HKD 0.01 each, equating to HKD 10.00 million.

Issued Share Capital • Outstanding ordinary shares (excluding treasury shares) stood at 515.47 million, identical to the prior month. • No new shares were issued, repurchased, or cancelled during April 2026. The company continues to hold zero treasury shares.

Public Float Compliance • Huakang Biomed confirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 25% of issued shares.

Capital Instruments • The company reported no movements or outstanding instruments under share option schemes, warrants, convertibles, or other share-issuance agreements.

Governance Confirmation • The board affirmed that any securities transactions conducted during the month were properly authorised and complied with all applicable listing rules and regulatory requirements.

With stable share capital and adherence to public-float standards, Huakang Biomed closed April 2026 without equity structure changes.